Trademarkia Logo

Canada

C$
Trademark Search in Canada
CYCLERION

View On IC.GC.CA

CYCLERION
REGISTERED

on 20 Oct 2023

Last Applicant/ Owned by

CYCLERION THERAPEUTICS INC.

301 Binney Street Cambridge, MA 02142

US

Serial Number

1948501 filed on 27th Feb 2019

Registration Number

TMA1204550 registered on 20th Oct 2023

Registration expiry Date

20th Oct 2033

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

CYCLERION

Trademark usage description

pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal sy Read More

Classification Information

Class [005]
Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, pharmaceutical preparations and substances that stimulate guanylate cyclases (sGC), increase the concentration of nitric oxide (NO), increase the concentration of cyclic guanosine monophosphate (cGMP), upregulate the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway; pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, pharmaceutical preparations and substances that utilize a synergistic interaction of the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds

Classification kind code

12

Class [042]
Pharmaceutical research and development; conducting pharmaceutical clinical trials; pharmaceutical product development

Classification kind code

12

Mark Details

Serial Number

1948501

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 190
on 27th Sept 2023		Registration Pending
Submitted for opposition 42
on 5th Jul 2023		Advertised
Submitted for opposition 26
on 8th Jun 2023		Approved
Submitted for opposition 27
on 8th Jun 2023		Approval Notice Sent
Submitted for opposition 22
on 20th Oct 2022		Search Recorded
Submitted for opposition 20
on 20th Oct 2022		Examiner's First Report
Submitted for opposition 287
on 28th Mar 2022		Pre-Assessment Letter Sent
Submitted for opposition 31
on 1st Mar 2019		Formalized
Submitted for opposition 30
on 27th Feb 2019		Filed
Submitted for opposition 1
on 27th Feb 2019		Created